Superworth

Exagen revenue XGN

Sales by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
$71.1M
Latest quarter, Q2 FY26
$19.9M
+16% on a year earlier
Fiscal year 2025
$66.6M
+20% on the year before

Exagen's revenue was $71.1M over the twelve months to Jun 30, 2026, up 21% on a year earlier.

In its latest quarter, Q2 FY26, it was $19.9M, up 16% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 10% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$66.6M+20%
FY2024$55.6M+6%
FY2023$52.5M+15%
FY2022$45.6M−6%
FY2021$48.3M+15%
FY2020$42M+4%
FY2019$40.4Mn/a
FY2018n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$19.9M+16%$71.1M
Q1 FY26$17.3M+12%$68.4M
Q4 FY25$16.6M+22%$66.6M
Q3 FY25$17.2M+38%$63.6M
Q2 FY25$17.2M+14%$58.9M
Q1 FY25$15.5M+8%$56.7M
Q4 FY24$13.7M−1%$55.6M
Q3 FY24$12.5M−7%$55.8M
Q2 FY24$15.1M+7%$56.7M
Q1 FY24$14.4M+28%$55.7M
Q4 FY23$13.8M+7%$52.5M
Q3 FY23$13.4M−9%$51.6M

Against its peers

Companies in Healthcare nearest Exagen's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
XGNExagen$71.1M+21% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
ELMDElectromed$73.8M+15% a year
PDEXPro DEX$79.6M+13% a year
UTMDUtah Medical Products$36.1M−7% a year
INFUInfuSystem$143.3M+2% a year
CYHCommunity Health Systems$11.7B−8% a year
EMBCEmbecta$1B−8% a year
VMDViemed Healthcare$301.6M+25% a year
CRMDCorMedix$462.2M+281% a year
Peer median$222.5M

Where Exagen ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Exagen

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.